CeriBell Receives FDA Clearance for Platform Software Update
MT Newswires Live
Yesterday
CeriBell (CBLL) has received the US Food and Drug Administration's approval for a software update that will add three capabilities to its namesake platform, the company said Wednesday.
The new capabilities are intended to simplify bedside electroencephalography interpretation, allowing clinicians to make "more informed" decisions, CeriBell said, adding that the approval has no age restriction.
The company expects to integrate the new features via an automatic software update in H1 2027, Chief Executive Jane Chao said.
CeriBell shares were down 1.1% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.